Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy

Menopausal Symptoms Clinical Trial

Official title:

Safety of Oral Micronized Progesterone Versus Norethisterone Acetate in Continuous Combination With Oral Estrogen as Menopausal Hormone Therapy - a Double-blind Randomized Study- PROBES Study (Progesterone Breast Endometrial Safety Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05586724
• Other study ID #: 2021-001624-17
• Status: Recruiting
• Phase: Phase 3
• Start date: February 25, 2022
• Est. completion date: December 2027

Study information

• Verified date: May 2023
• Source: Karolinska University Hospital
• Contact: Angelica L Hirschberg, MD, PhD
• Phone: +46 70 255 99 24
• Email: angelica.linden-hirschberg[@]regionstockholm.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

About one third of all women during menopausal transition have significant climacteric symptoms with considerable impact on quality of life. Meta-analysis has shown a beneficial risk profile with menopausal hormone therapy (MHT) for women 50 to 60 years. Still, there is a great need to find safe MHT able to control excessive endometrial stimulation by estrogen without stimulatory effects on the breast by the combination of estrogen/progestogen. Recent observational studies indicate a lower risk for breast cancer using micronized progesterone (mP) combined with estrogen but increased risk of endometrial cancer than by standard MHT. In a randomized trial, the balance between benefits and risks of mP vs. progestogens (norethisterone (NETA)) in combination with estrogen will be explored. For apparent reasons, long-term largescale clinical trials with endometrial and breast cancer as the primary endpoints, are not feasible. However, much knowledge can be obtained using relevant surrogate markers. Mammographic breast density is a strong risk factor for breast cancer, and endometrial hyperplasia is a strong risk factor for endometrial cancer. The primary objective is to compare the effects of one year treatment with mP versus progestogen, in combination with estradiol on mammographic breast density. Furthermore, to evaluate the effect of one year treatment with mP in continuous combination with estradiol on endometrial pathology (hyperplasia and cancer).

Description:

Postmenopausal women with climacteric symptoms will be randomized (1:1) to double blind treatment with oral mP or NETA in combination with oral estradiol. For the breast part, a power analysis revealed that 91 women/group would be sufficient to detect a significant difference in mammographic breast density between the groups at the 5%-level (two-sided) with 80% power. Considering the estimated rate of discontinuation and incomplete data, the target sample for the breast part is 260 patients. For the endometrial part, it is estimated that two or less women with serious adverse endometrial outcomes would result in an annual incidence of endometrial pathology of 0.67% or less with an upper bound of the one-sided 95% CI of 2.08% or less. Considering the estimated rate of discontinuation and incomplete data in the mP + estradiol group, the target sample for this part of the study is 390 patients. Mammography at baseline and after 12 months of treatment will be assessed by independent radiologists at the Karolinska University Hospital blinded to treatment. In addition to visual judgment, a computer based quantitative assessment will be performed. All mammograms will be anonymous so that the operator will be unaware of the patient's identity and type of treatment. Percentage change in mammographic density will be evaluated and compared between the groups. Endometrial biopsies at baseline and after 12 months of treatment will be evaluated by two independent pathologists at the Karolinska University Hospital for the incidence of endometrial pathology (hyperplasia or cancer) in the mP + estradiol group. Furthermore, immunostaining of the proliferation marker Ki-67, and other markers related to proliferation and apoptosis will be analyzed and compared between groups. Different validated self-assessment questionnaires will be used for screening of mood disorders like depression and anxiety, as well as quality of life and menopausal symptoms. The Patient Health Questionnaire (PHQ-9) is a tool for screening, diagnosing, and measuring the severity of depression. The Hospital Anxiety and Depression Scale (HADS) is an instrument for detecting states of depression and anxiety in the setting of a hospital or medical outpatient clinic. Health related quality of life is measured using the Psychological General Well-Being Index (PGWB). The Women's Health Questionnaire (WHQ) measures menopausal symptoms. The change in scores will be compared between the groups. Blood lipid profile, serum hormones, growth and metabolic factors, and coagulation factors will be analyzed. The gut- and vaginal microbiome will be characterized and compared between groups.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 390
• Est. completion date: December 2027
• Est. primary completion date: September 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 45 Years to 60 Years

Eligibility

Inclusion Criteria:

• Age 45-60 years
• BMI > 19 kg/m2 and = 32 kg/m2
• Intact uterus
• In case of previous MHT use, washout 8 weeks for oral MHT and 4 weeks for transdermal MHT or local estrogen treatment before screening
• Written informed consent

Exclusion Criteria:

• Previous history or risk factors for breast cancer, breast cancer in situ or abnormal mammogram at baseline as assessed clinically by a radiology expert
• Previous history or risk factors for endometrial cancer or hyperplasia or abnormal/proliferative endometrial biopsy at baseline
• Vaginal bleeding
• Any concomitant medical treatment except for well-controlled hypertension, non-insulin treated type 2 diabetes, asthma and hypothyroidism
• History or presence of or risk factor for cardiovascular disease including thromboembolic disorder or cerebrovascular disease
• History or presence of liver and gallbladder disease, familial hyperlipidemia, epilepsy or classical migraine with aura
• History or presence of clinically significant depression or other psychiatric disorder that might in anyway compromise the performance of the trial or undermine its scientific validity
• Porphyria, Systemic lupus erythematosus and otosclerosis
• Current use of MHT or local estrogen treatment
• Alcohol and/or drug abuse
• Clinically significant findings on physical and/or gynecological examination at baseline
• Hypersensitivity to any of the study treatments

Related Conditions & MeSH terms

• Menopausal Symptoms

Intervention

Drug:
• Micronized progesterone in continuous combination with oral estrogen
Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)
• Norethisterone acetate in continuous combination with oral estrogen
Capsule 0.5 mg NETA/ 1 mg estradiol (Activelle®) orally per day (encapsulated and identical to Estrofem® and one matched placebo to Utrogestan

Locations

Country	Name	City	State
Sweden	Karolinska University Hospital	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Angelica Lindén Hirschberg

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mammographic breast density	Percentage change in mammographic density	12 months treatment
Primary	Endometrial pathology	The incidence of endometrial pathology (hyperplasia or cancer)	12 months treatment
Secondary	Breast cell proliferation	Percentage change in breast cell proliferation (proliferation marker Ki-67)	12 months treatment
Secondary	Endometrial cell proliferation	Percentage change in endometrial cell proliferation (histology classification and proliferation marker Ki-67)	12 months treatment
Secondary	Endometrial thickness	Change in endometrial thickness by ultrasound	12 months treatment
Secondary	Bleeding pattern	Bleeding patterns registered in diary (number of days of bleedings)	3, 6, 9 and 12 months
Secondary	Gene and protein expression of growth factors and apoptosis markers in breast and endometrial tissue	Change in gene and protein expression (proliferation and apoptosis markers)	12 months treatment
Secondary	Depression (PHQ-9)	Change in score of PHQ-9: A 4-point scale where a larger value reflects more depression.	12 months treatment
Secondary	Anxiety (HADS)	Change in score of HADS: A 4-point scale where a larger value reflects more anxiety.	12 months treatment
Secondary	Quality of life (PGWB)	Change in score of PGWBI, where a where a higher score reflects more well-being.	12 months treatment
Secondary	Menopausal symptoms (WHQ)	WHQ: A 4-point scale where a larger value reflects less menopausal symptoms.	12 months treatment
Secondary	Serum levels of hormones, growth factors, lipids and coagulation factors.	Change in serum levels of these markers	12 months treatment
Secondary	Gut- and vaginal microbiome	Change in microbiome diversity and relative abundance of different microbial species.	12 months treatment